Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells

European Journal of Pharmacology

Volumn 600, Issue 1-3, 2008, Pages 140-147

  Gangoiti, María Virginia ^a   Cortizo, Ana María ^a   Arnol, Verónica ^a   Felice, Juan Ignacio ^a   McCarthy, Antonio Desmond ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Advanced glycation endproducts; Bisphosphonates; Osteoblasts; Proliferation; Reactive oxygen species

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GLYCATION; LOW DRUG DOSE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; RAT;

3T3 CELLS; ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CALCIUM CHANNELS, L-TYPE; CATTLE; CELL LINE; DIABETES COMPLICATIONS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSYLATION END PRODUCTS, ADVANCED; IMIDAZOLES; MICE; OSTEOBLASTS; OSTEOPOROSIS; RATS; REACTIVE OXYGEN SPECIES; SERUM ALBUMIN, BOVINE; TIME FACTORS;

EID: 55949126330     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.031     Document Type: Article

References (41)

1. Alikhani M., Alikhani Z., Boyd C., MacLellan C.M., Raptis M., and Liu R. Advanced glycation end products stimulate osteoblast apoptosis via MAP kinase and cytosolic apoptotic pathways. Bone 40 (2007) 345-353
2. Al-Mashat H.A., Kandru S., Liu R., Behl Y., Desta T., and Graves D.T. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity which contribute to impaired healing. Diabetes 55 (2006) 487-495
3. Boanini E., Torricelli P., Gazzano M., Giardino R., and Bigi A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 29 (2008) 790-796
4. Bouillon R. Diabetic bone disease. Calcif. Tissue Int. 49 (1991) 155-160
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
6. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
7. Cortizo A.M., and Etcheverry S.B. Vanadium derivatives act as growth factor-mimetic compounds upon differentiation and proliferation of osteoblast-like UMR106 cells. Mol. Cell Biochem. 145 (1995) 97-102
8. Cortizo A.M., Lettieri M.G., Barrio D.A., Mercer N., Etcheverry S.B., and McCarthy A.D. Advanced glycation endproducts (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol. Cell Biochem. 250 (2003) 1-10
9. Dagdelen S., Sener D., and Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv. Ther. 24 (2007) 1314-1320
10. Fromigué O., and Body J.J. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J. Endocrinol. Invest. 25 (2002) 539-546
11. Green J.R. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol. 44 (2005) 282-292
12. Krakauer J.C., McKenna M.J., Buderer N.F., Rao D.S., Whitehouse F.W., and Parfitt A.M. Bone loss and bone turnover in diabetes. Diabetes 44 (1995) 775-782
13. Mathov I., Plotkin L.I., Sgarlata C.L., Leoni J., and Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J. Bone Miner. Res. 16 (2001) 2050-2056
14. McCarthy A.D., Etcheverry S.B., Bruzzone L., and Cortizo A.M. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol. Cell Biochem. 170 (1997) 43-51
15. McCarthy A.D., Etcheverry S.B., and Cortizo A.M. Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol. 36 (1999) 45-52
16. McCarthy A.D., Etcheverry S.B., Bruzzone L., Lettieri G., Barrio D.A., and Cortizo A.M. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. B.M.C. Cell Biol. 2 (2001) 16
17. Molinuevo M.S., Barrio D.A., Cortizo A.M., and Etcheverry S.B. Antitumoral properties of two new vanadyl(IV) complexes on osteoblasts in culture. Role of apoptosis and oxidative stress. Cancer Chemother. Pharmacol. 53 (2004) 163-172
18. Molinuevo M.S., Bruzzone L., and Cortizo A.M. Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur. J. Pharmacol. 562 (2007) 28-33
19. Okajima T., Nakamura K., Zhang H., Ling N., Tanabe T., and Yasuda T. Sensitive colorimetric bioassays for insulin-like growth factor (IGF) stimulation of cell proliferation and glucose consumption: use in studies of IGF analogs. Endocrinology 130 (1992) 2201-2212
20. Okamoto T., Yamagishi S., Inagaki Y., Amano S., Takeuchi M., and Kikuchi S. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem. Biophys. Res. Commun. 297 (2002) 419-424
21. Partridge N.C., Alcorn D., Michelangeli V.P., Ryan G., and Martin T.J. Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res 43 (1983) 4308-4312
22. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., and Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104 (1999) 1363-1374
23. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
24. Quarles L.D., Yahay D.A., Lever L.W., Caton R., and Wenstrup R.J. Distinct proliferative and differentiated stages of murine MC3T3E1 cells in culture: an in vitro model of osteoblast development. J. Bone Miner. Res. 7 (1992) 683-692
25. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
26. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., and Monkkonen J. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
27. Schwartz A.V. Diabetes mellitus: does it affect bone?. Calcif. Tissue Int. 73 (2003) 515-519
28. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., and Schreiner P.J. Older women with Diabetes have an increased risk of fracture: a prospective study. J. Clin. Endocrinol. Metab. 86 (2001) 32-38
29. Spreafico A., Frediani B., Capperucci C., Gambera D., Ferrata P., and Baldi F. Anabolic effects and inhibition of interleukin 6 production induced by neridronate on human osteoblasts. Reumatismo 58 (2006) 288-300
30. Strotmeyer E.S., Cauley J.A., Schwartz A.V., Nevitt M.C., Resnick H.E., and Bauer D.C. Non traumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging and body composition study. Ann. Intern. Med. 165 (2005) 1612-1617
31. Tsuchimoto M., Azuma Y., Higuchi O., Sugimoto I., Hirata N., and Kiyoki M. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn. J. Pharmacol. 66 (1994) 25-33
32. Tullberg-Reinert H., and Jundt G. In situ measurement of collagen synthesis by human bone cells with a Sirius red-based colorimetric microassay: effects of transforming growth factor beta2 and ascorbic acid 2-phosphate. Histochem. Cell Biol. 112 (1999) 271-276
33. Ulrich P., and Cerami A. Protein glycation, diabetes, and aging. Recent. Prog. Horm. Res. 56 (2001) 1-21
34. Unno Y., Sakai M., Sakamoto Y., Kuniyasu A., Nakayama H., and Nagai R. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun. 325 (2004) 151-156
35. Vaisman D.N., McCarthy A.D., and Cortizo A.M. Bisphosphonates affect the growth, differentiation and cytoskeleton of UMR106 osteoblasts in culture. Osteoporos Int. 15 Suppl.1 (2004) S133
36. Vaisman D.N., McCarthy A.D., and Cortizo A.M. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol. Trace Elem. Res. 104 (2005) 131-140
37. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., and Grundker C. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Commun. 291 (2002) 680-686
38. Xiao G., Gopalakrishnan R., Jiang D., Reith E., Benson M.D., and Franceschi R.T. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J. Bone Miner. Res. 17 (2002) 101-110
39. Yamagishi S., Matsui T., Nakamura K., and Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int. J. Tissue React. 27 (2005) 189-195
40. Yamagishi S., Nakamura K., Matsui T., and Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med. Hypothesis 66 (2006) 273-275
41. Yamauchi M. World Health Organization. Absolute risk for fracture and WHO guideline. Treatment of patients with secondary osteoporosis. Clin. Calcium 17 (2007) 1106-1113